ASX - By Stock
|
ATH |
Re:
Alpha-synuclein induced synucleinopathies and NBIA's
|
|
brryh
|
10 |
3.1K |
6 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
10
|
3.1K
|
6
|
|
ASX - By Stock
|
ATH |
Re:
Stanford scientists: iron-calcium in mitochondrion as target in PD treatment
|
|
brryh
|
10 |
4.6K |
4 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
10
|
4.6K
|
4
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Notice Under Section 708A
|
|
brryh
|
48 |
12K |
1 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
48
|
12K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Notice Under Section 708A
|
|
brryh
|
48 |
12K |
4 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
48
|
12K
|
4
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Notice Under Section 708A
|
|
brryh
|
48 |
12K |
2 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
48
|
12K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Lancet: NLY01 does not work in PD
|
|
brryh
|
1 |
812 |
7 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
1
|
812
|
7
|
|
ASX - By Stock
|
ATH |
Re:
Stanford scientists: iron-calcium in mitochondrion as target in PD treatment
|
|
brryh
|
10 |
4.6K |
1 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
10
|
4.6K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Stanford scientists: iron-calcium in mitochondrion as target in PD treatment
|
|
brryh
|
10 |
4.6K |
4 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
10
|
4.6K
|
4
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Efficacy Data for ATH434 in a Primate Model of PD
|
|
brryh
|
32 |
10K |
1 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
32
|
10K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Efficacy Data for ATH434 in a Primate Model of PD
|
|
brryh
|
32 |
10K |
0 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
32
|
10K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Efficacy Data for ATH434 in a Primate Model of PD
|
|
brryh
|
32 |
10K |
3 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
32
|
10K
|
3
|
|
ASX - By Stock
|
ATH |
Endpoint News/ Merck Pharma
|
|
brryh
|
1 |
543 |
2 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
1
|
543
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Why Masters got PBT2 license???
|
|
brryh
|
4 |
1.1K |
1 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
4
|
1.1K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
News: ATH Alterity Therapeutics Seeks Trading Halt
|
|
brryh
|
18 |
5.7K |
0 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
18
|
5.7K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Why Masters got PBT2 license???
|
|
brryh
|
4 |
1.1K |
1 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
4
|
1.1K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
News: ATH Alterity Therapeutics Seeks Trading Halt
|
|
brryh
|
18 |
5.7K |
6 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
18
|
5.7K
|
6
|
|
ASX - By Stock
|
ATH |
Re:
Ann: New Data Demonstrating Novel Mechanisms of ATH434
|
|
brryh
|
4 |
1.2K |
1 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
4
|
1.2K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity Presents New Data on Multiple System Atrophy
|
|
brryh
|
5 |
1.8K |
4 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
5
|
1.8K
|
4
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity Granted New Composition of Matter Patent in Europe
|
|
brryh
|
14 |
4.3K |
2 |
26/08/23 |
26/08/23 |
ASX - By Stock
|
14
|
4.3K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Alterity Granted New Composition of Matter Patent in Europe
|
|
brryh
|
14 |
4.3K |
0 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
14
|
4.3K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Peter Marks in FDA: accelerated approvals for rare diseases
|
|
brryh
|
6 |
2.4K |
2 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
6
|
2.4K
|
2
|
|
ASX - By Stock
|
ATH |
ATH up today on Nasdaq $.415 (15.6%)
|
|
brryh
|
1 |
511 |
6 |
05/05/23 |
05/05/23 |
ASX - By Stock
|
1
|
511
|
6
|
|
ASX - By Stock
|
ATH |
Re:
The Fund: 2 new investments, but not ATH
|
|
brryh
|
6 |
2.1K |
0 |
29/04/23 |
29/04/23 |
ASX - By Stock
|
6
|
2.1K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
The Fund: 2 new investments, but not ATH
|
|
brryh
|
6 |
2.1K |
0 |
29/04/23 |
29/04/23 |
ASX - By Stock
|
6
|
2.1K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
The Fund: 2 new investments, but not ATH
|
|
brryh
|
6 |
2.1K |
4 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
6
|
2.1K
|
4
|
|
ASX - By Stock
|
ATH |
Re:
The Fund: 2 new investments, but not ATH
|
|
brryh
|
6 |
2.1K |
0 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
6
|
2.1K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: First Patient Enrolled in USA in Phase II Clinical Trial
|
|
brryh
|
1 |
782 |
1 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
1
|
782
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: First Patient Enrolled in Europe in Phase II Clinical trial
|
|
brryh
|
4 |
1.9K |
5 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
4
|
1.9K
|
5
|
|
ASX - By Stock
|
ATH |
Re:
ABRUPT, IMMEDIATE DEPARTURE OF BILLY DUNN, FDA NEUROSCIENCE CHIEF
|
|
brryh
|
4 |
2.2K |
4 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
4
|
2.2K
|
4
|
|
ASX - By Stock
|
ATH |
ABRUPT, IMMEDIATE DEPARTURE OF BILLY DUNN, FDA NEUROSCIENCE CHIEF
|
|
brryh
|
4 |
2.2K |
6 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
4
|
2.2K
|
6
|
|
ASX - By Stock
|
ATH |
Re:
Article today on NBC News.com/health
|
|
brryh
|
4 |
1.6K |
5 |
03/02/23 |
03/02/23 |
ASX - By Stock
|
4
|
1.6K
|
5
|
|
ASX - By Stock
|
ATH |
Re:
Article today on NBC News.com/health
|
|
brryh
|
4 |
1.6K |
0 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
4
|
1.6K
|
0
|
|
ASX - By Stock
|
ATH |
Article today on NBC News.com/health
|
|
brryh
|
4 |
1.6K |
3 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
4
|
1.6K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
A new PBT2 paper
|
|
brryh
|
7 |
2.4K |
4 |
27/01/23 |
27/01/23 |
ASX - By Stock
|
7
|
2.4K
|
4
|
|
ASX - By Stock
|
ATH |
Re:
Ann: ADS ratio change
|
|
brryh
|
4 |
1.7K |
1 |
24/01/23 |
24/01/23 |
ASX - By Stock
|
4
|
1.7K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: ADS ratio change
|
|
brryh
|
4 |
1.7K |
2 |
24/01/23 |
24/01/23 |
ASX - By Stock
|
4
|
1.7K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Dementia, new indication for ATHxxx?
|
|
brryh
|
8 |
3.5K |
10 |
10/01/23 |
10/01/23 |
ASX - By Stock
|
8
|
3.5K
|
10
|
|
ASX - By Stock
|
ATH |
Re:
Dementia, new indication for ATHxxx?
|
|
brryh
|
8 |
3.5K |
1 |
31/12/22 |
31/12/22 |
ASX - By Stock
|
8
|
3.5K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: New US patent for compounds to treat neurodegeneration
|
|
brryh
|
9 |
3.4K |
1 |
30/12/22 |
30/12/22 |
ASX - By Stock
|
9
|
3.4K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Antibiotic Resistance Market worth $18.34 Billion by 2030
|
|
brryh
|
5 |
2.4K |
4 |
17/12/22 |
17/12/22 |
ASX - By Stock
|
5
|
2.4K
|
4
|
|
ASX - By Stock
|
ATH |
Re:
Antimicrobial awareness week 18-24, November, 2022
|
|
brryh
|
1 |
710 |
2 |
05/12/22 |
05/12/22 |
ASX - By Stock
|
1
|
710
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Shorts down from 230K to 154K
|
|
brryh
|
2 |
997 |
4 |
28/11/22 |
28/11/22 |
ASX - By Stock
|
2
|
997
|
4
|
|
ASX - By Stock
|
ATH |
Re:
No news, not even from the "Fund".
|
|
brryh
|
4 |
1.7K |
1 |
13/10/22 |
13/10/22 |
ASX - By Stock
|
4
|
1.7K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Appendix 4E & Annual Report 2022
|
|
brryh
|
13 |
6.0K |
1 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
13
|
6.0K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Proposed issue of securities - ATH
|
|
brryh
|
24 |
9.2K |
0 |
23/09/22 |
23/09/22 |
ASX - By Stock
|
24
|
9.2K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Proposed issue of securities - ATH
|
|
brryh
|
24 |
9.2K |
1 |
23/09/22 |
23/09/22 |
ASX - By Stock
|
24
|
9.2K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Proposed issue of securities - ATH
|
|
brryh
|
24 |
9.2K |
0 |
23/09/22 |
23/09/22 |
ASX - By Stock
|
24
|
9.2K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Proposed issue of securities - ATH
|
|
brryh
|
24 |
9.2K |
0 |
22/09/22 |
22/09/22 |
ASX - By Stock
|
24
|
9.2K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Mitochondrion dysfunctions in early PD
|
|
brryh
|
4 |
1.8K |
3 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
4
|
1.8K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Mitochondrion dysfunctions in early PD
|
|
brryh
|
4 |
1.8K |
1 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
4
|
1.8K
|
1
|
|